- Dewey TM, Brown DL, Herbert MA, et al. Effect of concomitant coronary artery disease on procedural and late outcomes of transcatheter aortic valve implantation. Ann Thorac Surg. 2010;89(3):758–767. doi:10.1016/j.athoracsur.2009.12.033.
- D'Ascenzo F, Verardi R, Visconti M, et al. Independent impact of extent of coronary artery disease and percutaneous revascularisation on 30-day and one-year mortality after TAVI: a meta-analysis of adjusted observational results. EuroIntervention. 2018;14(11):e1169–e1177. doi:10.4244/EIJ-D-18-00098.
- Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561–632. doi:10.1093/eurheartj/ehab395.
- Ribeiro HB, Nombela-Franco L, Muñoz-García AJ, et al. Predictors and impact of myocardial injury after transcatheter aortic valve replacement. J Am Coll Cardiol. 2015;66(19):2075–2088. doi:10.1016/j.jacc.2015.08.881.
- Aarts HM, Van Hemert ND, Meijs TA, et al. Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: a systematic review and meta-analysis. Neth Heart J. 2023. doi:10.1007/s12471-023-01824-w.
- Park DY, An S, Arif AW, Saini A, Golzar Y. Impact of same-admission percutaneous coronary intervention on periprocedural outcomes of transcatheter aortic valve implantation. Proc (Bayl Univ Med Cent). 2024;37(1). doi:10.1080/08998280.2023.2273742.
- van Nieuwkerk AC, Aarts HM, Hemelrijk KI, et al. Bleeding in patients undergoing transfemoral transcatheter aortic valve replacement: incidence, trends, clinical outcomes and predictors. JACC Cardiovasc Interv. 2023.
- Rheude T, Costa G, Ribichini FL, et al. Comparison of different percutaneous revascularisation timing strategies in patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2023;19(7):589–599. doi:10.4244/EIJ-D-23-00186.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 37, 2024 - Issue 1
Original Research: Cardiology
Dealing with concomitant coronary artery disease in TAVI patients—should we treat it all in one go?
Hugo M. Aartsa Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands;b Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
https://orcid.org/0000-0003-0852-8275
, MSchttps://orcid.org/0000-0003-0852-8275, Ronak Delewia Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlandshttps://orcid.org/0000-0001-6070-9423
, MD, PhDhttps://orcid.org/0000-0001-6070-9423 & Bimmer E.P.M. Claessena Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The NetherlandsCorrespondence[email protected]
https://orcid.org/0000-0002-1703-7921
, MD, PhDhttps://orcid.org/0000-0002-1703-7921